Reading NKTR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NKTR free→Reading NKTR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NKTR free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Peer multiples imply a price about 5% above where it trades (it looks cheap on this basis); the read is fair, but weakening. Key factors to watch include the performance of sector bellwethers like VRTX, REGN, and ARGX, as their earnings guidance could influence NKTR's momentum. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $60.27. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $59 NKTR trades at 12× p/s, in line with its 9× p/s peer median. Our $61 fair value reflects that, low confidence. Analysts: $80–$192. Not investment advice.
(median $140.00) · 5 analysts · as of 2026-05-11
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 3% below a flat-multiple fair value, well above our forecast of about -31%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.29x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
11 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-2.04 → $-2.04 (+0.1% / 30d). 2 raised, 0 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 90% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$216.
How much price usually moves either way.
On a bad day, this stock has moved -$672.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,654.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation changed from "full" to "fair." Risk fell. The sector backdrop remains a headwind. Earnings quality is still loss-making. Management is volatile and capital-unfriendly.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This report will show if Nektar's financial situation is improving or worsening. Investors will look for signs of revenue growth or continued losses.
Confirms one read:Earnings report shows revenue growth year over year or a reduction in losses.
Confirms the other:The earnings report shows losses or lower revenue compared to last year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NKTR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026. Ms. Gardiner, a partner of FLG Partners, LLC, a leading chief financial officer services firm (“FLG”), has served as interim Chief Financial Officer of the Company since April 2023.…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NKTR Nektar Therapeutics | Typical Show detailsSector percentile: 46 of 100 | fair | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 79 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 78 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Nektar entered an underwriting agreement for a stock offering with several underwriters.
Newly stated in 2026-Q2. Nektar entered an underwriting agreement for a stock offering, indicating a strategic move to raise capital. Despite this, the company's revenue decreased from $21.8M in 2025-Q4 to $10.9M in 2026-Q1, reflecting financial pressures. The effectiveness of this capital strategy is yet to be determined.
“Nektar entered an underwriting agreement for a stock offering.”
Nektar announced 52-week topline results from the REZOLVE-AA study of rezpegaldesleukin.
Newly stated in 2026-Q2. Nektar announced results from the REZOLVE-AA study, highlighting its focus on product development. However, the financials show a net income of -$44.9M in 2026-Q1, suggesting ongoing financial challenges. The impact of these study results on the company's financial trajectory remains uncertain.
“Nektar announced 52-week topline results from the REZOLVE-AA study.”
Why it matters: If the health care sector's revenue growth picks up, it could help Nektar's performance. A strong sector can lift individual stocks.
Confirms:Health care sector revenue growth speeds up to 10% or more.
Disproves:Sector revenue growth keeps slowing down or stays under 10%.
Results of Operations and Financial Condition. On May 7, 2026, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2026. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Entry Into a Material Definitive Agreement. On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “…
Entry into a Material Definitive Agreement. On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,532,609 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 p…
Other Events. Phase 2b REZOLVE-AA Results – Blinded 16-Week Treatment Extension Period On April 20, 2026, the Company announced 52-week topline results from the blinded 16-week treatment extension period of its REZOLVE-AA study of rezpegaldesleukin. REZOLVE-AA is a global study being conducted in 92 patients with severe-to-very-severe alopecia areata. During the initial 36-week induction phase, patients were randomized (3:3:2) to receive one of two rezpegaldesleukin doses or placebo, administ…